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ABSTRACT
Objective: This study aimed to determine the metformin plasma steady-state concentration (PSSC) either trough and peak level in Type 2 diabetes 
mellitus patients with obesity and the impact of SLC22A1 gene organic cation transporter 1 (OCT) rs628031 A>G on PSSC of metformin.
Methods: Validated reversed-phase high-performance liquid chromatography method with ultraviolet detector was used to determine the metformin 
PSSC, as well as genotype variation was performed using the restriction fragment length polymorphisms-polymerase chain reaction method.
Results: A total of 13 patients were recruited from five Primary Health Centers in Yogyakarta Province of Indonesia. The results showed that the 
means of their trough and peak PSSC were 0.285±0.192 and 1.175±0.814 µg/ml, respectively. Only 10 patients (77%) had peak PSSC within the 
plasma therapeutic level (PTL) of metformin, and 14-fold variability was observed for the peak PSSC. None of the patients achieved the PTL of 
metformin with regard to their trough PSSC. The PSSC of metformin was independent of the OCT1 genotype in rs628031 (A>G) 408M/V SLC22A1.
Conclusion: This study found a huge variability in the trough concentration of metformin (>100-fold) and 14-fold for the peak PSSC, and no impact 
of a variant of rs628013 SLC22A1 OCT1 on metformin PSSC was revealed.
Keywords: Metformin, Steady-state pharmacokinetics, Obesity, Type 2 diabetes mellitus.
INTRODUCTION
Metformin is the chosen oral antidiabetics to treat Type 2 diabetes 
mellitus (T2DM) patients with obesity [1]. In addition to its ability 
in reducing hemoglobin A1c (HbA1c) level up to 1-2% and in 
improving insulin sensitivity, metformin has been known to be able to 
reduce body weight slightly. Those positive effects, along with lower 
incidence of hypoglycemia, have placed metformin in the first line of 
T2DM treatment, particularly, in patients with obesity [2,3]. However, 
the current dosing of metformin mostly refers to the drug-dosing 
data resulted from clinical studies on average-weight patients, and 
hence it is less clear to obtain metformin dosing-guidelines for the 
obese [4]. In addition, the results of Garber et al. demonstrated that 
the effectiveness of metformin as antidiabetic was correlated with its 
doses [5].
Metformin is available in the plasma largely as hydrophilic cation 
making it an unmetabolized drug with low plasma protein-binding so 
that its clearance is mostly affected only by cardiac output and renal 
function [6,7]. Therefore, the pharmacokinetic parameters of metformin 
could be changed in obese individuals, especially for the renal clearance 
because of increased glomerular filtration and tubular secretion [7,8]. 
Despite its wide therapeutic range, which is 0.75-5.00 µg/ml [9,10], it 
is suggested that the pharmacokinetic variability in an individualizing 
dosage of metformin should also be considered to gain optimal 
effectiveness without lactic acidosis [7]. In a clinical setting, the usual 
pharmacokinetic parameter to adjust dosage regimen in multiple drug 
administration is the drug steady-state level.
Several studies of plasma steady-state concentration (PSSC) of 
metformin have been conducted. A study of metformin trough PSSC 
in patients with unknown body mass index (BMI) was conducted 
on varying renal functions and doses [11]. Meanwhile, two studies 
investigated the low function of transporters, which is responsible 
for influx-efflux metformin in hepatocyte, and its influence on trough 
concentration of metformin [12,13]. However, studies on the peak 
steady-state level of metformin that could be used to estimate the 
maximum doses of metformin and its variability that could reflect the 
reduced-function of transporters mainly in the distribution process of 
metformin have never been conducted.
One of the transporters mediating the intestinal uptake of metformin [14] 
as well as the hepatic uptake of metformin across the sinusoidal 
membrane primarily is organic cation transporters 1 (OCT) [15]. 
Considerable works have been carried out with the OCT1 and its impact 
on both of pharmacokinetics as well as the response of metformin. 
Studies of genetic variants in specific population may illuminate 
important polymorphisms on metformin therapy [15]. Up to the present, 
investigation of OCT1 polymorphisms in Asian T2DM patients has been 
conducted in limited study. Results of Umamaheswaran et al. found a 
high frequency of the single nucleotide polymorphism (SNP) rs628031 
OCT1 in Indian Population [16]. This variant could play an important 
role in pharmacokinetics and therapeutic response of metformin.
Alteration of pharmacokinetic parameters in obese patients, as well as 
reduced function of metformin transporters potentially, influence the 
obtained metformin PSSC, and further dose adjustment is required 
in case the intended PSCC and glycemic control are not reached. 
Considering the limited studies on PSSC of metformin in obese patients 
in Asian population as well as the existence of variant transporters of 
metformin that could affect both metformin pharmacokinetics and 
pharmacodynamics, this preliminary study aimed to determine the 
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PSSC as well as the impact of rs628031 408M/V SLC22A1 OCT1 on 
metformin PSSC in Indonesian T2DM patients with obesity.
METHODS
T2DM patients with obesity, indicated by the BMI of ≥30 kg/m2, were 
recruited from five Primary Health Centres during January-November 
2015 in Yogyakarta province, Indonesia. Patients aged 35-60 years old, 
receiving a therapy of generic metformin at a dose of 500 mg every 12 hrs 
daily for at least 2 weeks as either a monotherapy or in combination 
with other antidiabetics, and willing to participate in the study were 
included. Patients with creatinine serum >1.00 mg/dL, history of 
chronic liver diseases, medication having potentially pharmacokinetic 
interaction with metformin such as cimetidine, furosemide, 
nifedipine [17], and systemic steroid treatment because of its glycemic 
uncontrolled effect [18] and patients not adhering to metformin therapy 
were excluded. Ethics approval for this research has been granted by 
the Faculty of Medicine – University of Gadjah Mada Ethics Committee. 
Written informed consent was obtained from all subjects.
Steady state of metformin measurement
To measure the trough PSSC of metformin, blood sample was 
taken immediately before administrating the next dose (pre-dose). 
Subsequently, the blood sample taken 3.5-4 hrs after metformin 
administration was used to measure the peak PSSC (post-dose). 
Determination of metformin plasma concentrations was carried 
out using validated reversed-phase high-performance liquid 
chromatography assay with a Sunfire® C-18 column, 4.6 × 150 mm × 5 µm 
from waters, and SM7 injector with ultraviolet (UV) detector at 233 nm 
of wavelength. The mobile phase used a mixture of 45% acetonitrile 
and 55% buffer phosphate (6 mM KH2PO4, 6 mM sodium lauryl 
sulfate). All of the parameters for bioanalytical method have fulfilled 
the Guidance for Bioanalytical Method Validation from FDA. The 
linearity of the standard curve was (r) 0.9999, and the accuracy value 
(% difference) was <15%. Meanwhile, the value of precision (CV) was 
<15%. The obtained selectivity value (CV) was <15%, while the CV of 
recovery ranged 1.22-1.89% (unpublished observations). The obtained 
PSSCs were used to calculate metformin elimination rate by following 
one-compartment pharmacokinetic model [19]. The equation for 
elimination rate is [20]:
max,ss trough,ss
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Genomic DNA was isolated from whole blood, and genotyping for 
(rs rs628031 A→G) variations was performed using the restriction 
fragment length polymorphism-polymerase chain reaction (PCR) 
method. For PCR amplification, the following primers were used: 
Forward 5’-TTTCTTCAGTCTCTGACTCATGCC-3’ and reverse 
5’-AAAAAACTTTGTAGACAAAGGTAGCACC-3’. A thermo Scientific® 5020 
PCR was used for the amplification with PCR conditions as follows: 
Initial denaturation at 94°C for 5 minutes followed by 30 cycles of 
denaturation at 94°C for 30 seconds, annealing at 63°C for 45 seconds, 
primer extension for 1 minutes at 72°C, and final extension at 72°C for 
10 minutes. The PCR products were digested with MscI. The digestion 
of 397 bp amplicon of rs628031 GG genotype resulted in 397 bp 
fragments, and the AA genotype remained 210 and 187 bp, whereas the 
heterozygous genotype was 187, 210, 397 bp fragments. The accuracy 
and reliability of all the genotyping methods have been confirmed by 
direct DNA sequencing in the previous study [16].
Control glycemic assay
For patients receiving metformin as a single therapy for 6 weeks, the 
parameters of glycemic responses were also assessed by measuring 
fasting blood glucose (FBG) and glycated albumin (GA) level. 
The GA was determined using ELISA reader ADVIA®, and UV/VIS 
spectrophotometry was utilized for the FBG. The intended FBG was 
defined as <100 mg/dl while the GA was <16% [21].
Statistical analysis
The results were expressed as mean±standard deviation. The peak PSSC 
of metformin was not normally distributed, thus the Mann–Whitney 
U-test was used to assess the difference mean among the groups, and 
the Spearman test was for the numerical correlation. As the nature 
of the study was slightly explorative, no sample size calculation was 
performed, but the size of the study population was estimated from a 
previous pharmacokinetic study of antibiotics in obese patients [22] as 
well as genetic variations in specific patients [13].
RESULTS
Thirteen T2DM patients were included in this study, in which all 
patients were female, and the patients’ characteristics are presented 
in Table 1. Regarding the BMI, most patients were within the category 
of moderate obesity with age under 50-year-old. Most of the patients 
had estimated glomerular filtration rate (GFR) ≥100 ml/min. The 
proportion of patients diagnosed as having T2DM for more or <5 years 
was quite similar. However, more patients used metformin twice daily 
as oral antidiabetics for more than 6 weeks before participating in 
this study, and so did patients with variant heterozygote Met/Val in 
SLC22A1.
In addition, metformin users had higher (1.98-fold) peak PSSC of 
metformin than patients with a combination therapy (p<0.05). It was 
not significantly different for the other characteristic groups in either 
trough or peak level of metformin.
Fig. 1 displays the achieved trough and peak PSSC of metformin 
for each patient participating in this study. The average sampling 
time for the determination of trough PSSC in this study was 
12.18±0.24 hrs after previous metformin administration, and the 
obtained PSSC ranged between 0.003 and 0.586 µg/ml. Meanwhile, the 
average sampling time to determine the peak PSSC was 3.83±0.09 hrs 
after the next administration of metformin, and the peak PSSC ranged 
0.240-3.359 µg/ml. From the obtained PSSC, an elimination rate of 
metformin was calculated accordingly, and it was found that the average 
elimination rate of metformin among the 13 patients was 0.15±0.11/hr.
With regard to the trough PSSC, it was found that no patients reached the 
metformin plasma therapeutic level (PTL), and only 10 patients (77%) 
whose peak PSSC reached metformin PTL were identified. However, the 
obtained PSSC in this study can be further used to estimate the adequate 
dose of metformin. By assuming that metformin followed the first order 
kinetics, the pharmacokinetic parameters of metformin such as half 
time, volume of distribution, and renal clearance were unchanged in 
patients. Hence, the recommended PTL of metformin with respect to the 
avoidance of lactic acidosis, which is PSSC >5 µg/mL, and the maximum 
Fig. 1: Observed metformin plasma steady state concentration 
among 13 patients included in the study compared to the upper 
limit and minimum effective concentration of metformin
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dose of metformin for T2DM patients with obesity can be calculated 
accordingly. Given that the average peak PSSC obtained in this study 
was 1.175±0.814 µg/mL, the estimated maximum dose of metformin 
for T2DM patients with obesity was 2513.83 mg ∞ 2500 mg daily. 
Unfortunately, the minimum dose could not be calculated because of 
the large variability (>100-fold) of the trough PSSC in this study [11]. As 
listed in Table 1, only 6 patients received metformin as a single therapy. 
For these 6 patients, an assessment of glycemic control was performed 
by using two parameters: The change of FBG and GA. It can be shown in 
Table 2 that no patient achieved the intended FBG, and only 2 patients had 
GA value within the defined range. In addition, due to the small number of 
cases in glycemic control assay, no formal analysis was conducted.
DISCUSSION
To conduct monitoring and evaluation of administered drug therapy 
is very important to ensure that the defined therapeutic responses 
have been achieved [23]. The most important aspect leading to the 
need of monitoring and evaluation for patients receiving metformin 
therapy is the variability of metformin pharmacokinetics and the risk of 
lactic acidosis in those patients with metformin plasma concentration 
>5 µg/mL even in patients with normal renal function [24].
Other than the specific characteristics of obesity, the limited number 
of patients receiving metformin as a single therapy was the substantial 
reason for getting limited research subjects. Although several 
approaches have been conducted to obtain male patients for this study, 
no male patients were willing to participate; as a result, all recruited 
patients were female. Therefore, this study cannot rule out significant 
gender differences in the metformin PSSC of obese patients.
Based on the obtained PSSC in this study, the elimination rate was 
estimated at 0.15±0.11/h, and it was higher than the elimination 
rate stated in literature, that is 0.112/h [9], probably indicating that 
metformin is excreted more effectively in obese individuals owing to 
increased GFR and tubular excretion than in patients with normal body 
weight.
One important finding of this study is that there were no patients reaching 
the PTL with regard to the trough PSSC. This means that the administered 
dose of metformin was inadequate to achieve the intended therapeutic 
level, which potentially leads to the failure of obtaining defined 
therapeutic responses [23]. Considering that the half-life of metformin is 
approximately 5 hrs in T2DM patients with normal renal function [25], 
administering conventional dosage form of metformin every 12 hrs (2.4-
fold) resulted in trough PSSC [20] that is under the minimum effective 
concentration of metformin. Researches on pharmacokinetics and 
pharmacodynamics modeling exhibit a correlation between metformin 
plasma levels and glycemic responses [26]. In addition, doses were a 
dependent of the glycemic response of metformin [5].
Furthermore, this research found that only 10 patients (77%) had peak 
PSSC within the PTL while none of the patients had metformin levels 
>5 mg/mL indicating low risk of lactic acidosis. Although the plasma 
level of metformin can be used to estimate the occurrence of lactic 
acidosis, other parameters such as symptoms of nausea and fatigue as 
well as abnormalities in lactate levels (plasma lactate levels >4 mmol/L 
and/or pH <7.37) should also be confirmed [27]. PSCC <5 mg/mL was 
observed by Duong et al. in dosing sumulations for patients with ClCr 
30 ml/min receiving metformin 1000 mg daily [10]. Commonly, the risk 
of lactic acidosis due to metformin administration increases when the 
Table 1: Characteristics of patients
Characteristics Number (%) Trough PSSC±SD (µg/ml) p Peak PSSC±SD (µg/ml) p
Age (years)
<50 8 (61.5) 0.2935±0.1611 0.850 1.1291±0.9822 0.464
≥50 5 (38.5) 0.2714±0.2553 1.2496±0.5361
BMI (kg/m2)
30-35 10 (76.9) 0.2739±0.1732 0.721 1.0912±0.4795 0.612
≥35 3 (23.1) 0.3220±0.2904 1.4563±1.6689
eGFR (ml/min/1.73 m2)
70-100 4 (30.8) 0.2235±0.1841 0.466 1.2930±0.6879 0.280
≥100 9 (69.2) 0.3123±0.2001 1.1232±0.8978
Duration of T2DM (years)
<5 7 (53.8) 0.2520±0.1816 0.528 1.1566±1.0248 0.475
≥5 6 (46.2) 0.3235±0.2142 1.1975±0.5729
Duration of metformin (weeks)a
2-<6 6 (46.2) 0.2498±0.2035 0.565 1.3250±1.1191 0.886
≥6 7 (53.8) 0.3151±0.1929 1.0473±0.4893
Metformin regimen
Single 6 (46.2) 0.3543±0.1275 0.245 1.6020±0.9466 0.046*
In combination with other antidiabetics 7 (53.8) 0.2256±0.2270 0.8099±0.4899
Genotypeb
GG 3 (25.0) 0.2433±0.2361 0.862 1.3693±0.9226 0.166
AG 9 (75.0) 0.2654±0.1707 0.7290±0.1366
*p<0.05, aAt dose of 500 mg every 12 hrs, b1 patient with wild-type AA. PSSC: Plasma steady-state concentration, T2DM: Type 2 diabetes mellitus, 
eGFR: Estimated glomerular filtration rate, BMI: Body mass index
Table 2: Glycemic control responses among 6 patients after receiving a single therapy of metformin 500 mg every 12 hrs
S.No. Genotype Baseline of FBG (mg/dL) FBG after 6 weeks (mg/dL) Baseline of GA (%) GA after 6 weeks (%)
1 AG 108 105 15.96 15.45
2 AG 135 127 17.89 18.39
3 GG 152 131 16.59 15.53
4 AG 119 173 17.36 19.92
5 GG 175 268 24.37 22.1
6 AG 199 189 22.27 23.21
Spearman test: Between baseline FBG and GA (p=0.072, r=0.771); between FBG and GA after metformin administered for 6 weeks (p<0.05, r=0.886). FBG: Fasting blood 
glucose, GA: Glycated albumin
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tissue suffers from hypoxia as in the case of myocardial infarction, acute 
left heart failure or septicemia as well as renal or liver failure [27,28].
Although this research was unable to estimate the metformin dose based 
on a pharmacokinetics-pharmacodynamics profile due to the limited 
number of patients, the findings can be considered for a maximum 
dose recommendation of metformin in T2DM patients with obesity. 
The maximum twice daily dosing of metformin in T2DM patients with 
obesity based on the observed peak PSSC in this research was 2500 mg 
daily, and this is almost similar to the recommended maximum dose 
of metformin for adult patients with average body weight stated in the 
literature (2550 mg/day) [18].
In addition, the unachieved PTL in regard to the trough PSSC of 
metformin in this research indicated that the administered daily dose 
of 1000 mg metformin was inadequate, and this was further proved 
by a decrease of FBG only in 4 patients and 3 patients for the GA after 
metformin administration for 6 weeks. In a study involving 45 obese 
patients with T2DM, a significant reduction of FBG was observed after 
treated with metformin 500 mg twice daily for 1 year [29]. Yasser et al. 
found 18.3% reduction of HbA1c in 10 patients with newly diagnosed 
of T2DM after receiving 1000 mg metformin [30]. The difference on the 
duration of metformin administration, the baseline of glycemic index, as 
well as involved patients with normal renal function could be the reasons 
of this present results. In addition, since GA reflects a shorter glycemic 
control resulted from shorter life span of albumin (17 days) compared 
to erythrocyte [31], make GA is an intermediate-term glycation index. 
A study including 18 patients with T2DM showed a GA reduction up to 
8.1% after being administered with metformin and monitored every 
4 weeks for 24 weeks [32]. Because of limited sample size, no statistical 
analysis for the glycemic control was performed in this study.
A higher peak PSSC of metformin instead of trough level in variant 
homozygote GG group was found in this study (p=0.166). OCT1 (gene 
SLC22A1) is expressed on the basolateral membrane and cytoplasm of 
the enterocytes and predominantly found in hepatocytes [14]. Since the 
variant homozygote have greater impact to protein function, thereby 
OCT1 reduced-function may contribute to a decrease in influx of 
metformin to hepatocytes and result in higher peak PSSC of metformin 
than in heterozygote variant group in this study.
Meanwhile, OCT1 is also expressed on the apical and subapical domain 
side of both the proximal and the distal tubules in the kidney [33], so it 
plays an important role in the renal clearance of metformin. In the present 
study, there was no impact on metformin PSSC of the frequent OCT1 SNP 
rs628031 (408M/V), which was contrary to the result of Shikata et al. 
that demonstrated lower expression of mRNA in OCT1 in the hepatocyte 
of human liver with 408M/V variant in SLC22A1 [34]. Since OCT1 is the 
main transporter responsible in the influx process of metformin into 
hepatocyte, the existence of variance leads to a reduced function of the 
transporter. Consequently, metformin in a level higher than that in wild-
type patients was observed. The smaller size of sample and number of 
observation could explain the insignificant difference in these findings.
This present study also revealed a quite large number of frequency of 
SNP rs628031 OCT1 in Indonesian T2DM patients, so further studies 
about the impact of this variant on gastrointestinal side effect and risk 
of hypoglycemia events as already reported in several studies [35,36] 
should be conducted for Indonesian population. As this research also 
found a variability of metformin peak PSSC, as well as a significantly 
higher level in metformin users, a pharmacogenetic and detailed 
pharmacokinetic study on monotherapy compared to combination 
therapy with sulfonylurea, are required to improve the therapeutic 
management of T2DM patients receiving metformin.
CONCLUSION
This study found a huge variability in the trough concentration of 
metformin (>100-fold) and 14-fold for the peak PSSC. The PSSC of 
metformin was independent of the OCT1 genotype in rs628031 408M/V 
SLC22A1. This study indicated that the maximum doses of metformin 
were relatively similar to what is listed in the literature; also, the 
prescription of metformin with twice daily dose of 500 mg was 
inadequate for T2DM patients with obesity. However, due to the small 
size of samples, further studies are needed to draw firm conclusions.
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